American CryoStem Corporation (CRYO) is a clinical-stage biotechnology company, developing and delivering autologous (own self) regenerative therapies to treat diseases and conditions with significant unmet medical needs. We are prioritizing research targets and biological drug candidates where the disease biology is understood, and where our suite of technologies has the potential to make a difference. We are currently focused on mitigating the deleterious effects of post-concussion syndrome: https://clinicaltrials.gov/ct2/show/NCT04744051 and Long COVID/ PASC: Post Acute Sequelae of SARS-CoV-2 https://clinicaltrials.gov/ct2/show/NCT05669261 Translating Technology into Therapeutic Treatments™ Our core proprietary "end-to-end" patented technology platform consists of the “Collection-Processing-Cryobanking and Delivery to Point-of-Care” of Adipose Tissue (AT) and Adipose-Derived Mesenchymal Stem Cells (MSCs). Our Platform is configured to produce large quantities of autologous mesenchymal stem cells for treatments as needed, "on-demand". Through a single tissue collection, an autologous master cell sample is manufactured and cryopreserved for a lifetime of personalized treatments. Naturally, pure and simple.™